INR 235.95
(4.89%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 438.55 Million INR | -60.37% |
2022 | 1.1 Billion INR | 5.16% |
2021 | 1.05 Billion INR | 19.38% |
2020 | 881.55 Million INR | -6.77% |
2019 | 945.6 Million INR | 10.67% |
2018 | 854.42 Million INR | 11.62% |
2017 | 765.44 Million INR | -5.27% |
2016 | 808.03 Million INR | 7.66% |
2015 | 750.56 Million INR | 18.5% |
2014 | 633.37 Million INR | -11.16% |
2013 | 712.92 Million INR | -2.28% |
2012 | 729.55 Million INR | -6.33% |
2011 | 778.89 Million INR | 19.16% |
2010 | 653.64 Million INR | 30.48% |
2009 | 500.94 Million INR | 17.0% |
2008 | 428.16 Million INR | -9.37% |
2007 | 472.44 Million INR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 117.33 Million INR | 24.38% |
2024 Q2 | 343.87 Million INR | 12.9% |
2023 Q3 | 245.09 Million INR | -15.52% |
2023 FY | 438.55 Million INR | -60.37% |
2023 Q1 | 296.2 Million INR | 9.3% |
2023 Q4 | 94.33 Million INR | -61.51% |
2023 Q2 | 290.1 Million INR | -2.06% |
2022 Q3 | 289.96 Million INR | 7.83% |
2022 FY | 1.1 Billion INR | 5.16% |
2022 Q4 | 270.99 Million INR | -6.54% |
2022 Q2 | 268.89 Million INR | -6.78% |
2022 Q1 | 288.46 Million INR | 5.38% |
2021 Q4 | 273.72 Million INR | -0.46% |
2021 Q1 | 244.37 Million INR | 11.51% |
2021 Q2 | 259.27 Million INR | 6.1% |
2021 Q3 | 274.99 Million INR | 6.06% |
2021 FY | 1.05 Billion INR | 19.38% |
2020 Q3 | 256.08 Million INR | 7.15% |
2020 FY | 881.55 Million INR | -6.77% |
2020 Q1 | 167.34 Million INR | -17.85% |
2020 Q2 | 238.98 Million INR | 42.81% |
2020 Q4 | 219.14 Million INR | -14.42% |
2019 Q1 | 247.92 Million INR | 17.03% |
2019 Q4 | 203.69 Million INR | -20.81% |
2019 FY | 945.6 Million INR | 10.67% |
2019 Q3 | 257.2 Million INR | 8.62% |
2019 Q2 | 236.78 Million INR | -4.49% |
2018 Q2 | 220.58 Million INR | 9.97% |
2018 Q4 | 211.83 Million INR | -3.53% |
2018 Q3 | 219.58 Million INR | -0.45% |
2018 FY | 854.42 Million INR | 11.62% |
2018 Q1 | 200.59 Million INR | -10.93% |
2017 Q4 | 225.19 Million INR | 13.65% |
2017 FY | 765.44 Million INR | -5.27% |
2017 Q3 | 198.14 Million INR | 15.55% |
2017 Q2 | 171.47 Million INR | 1.4% |
2017 Q1 | 169.1 Million INR | -17.34% |
2016 Q1 | 222.26 Million INR | 6.28% |
2016 Q3 | 166.02 Million INR | -23.29% |
2016 Q4 | 204.56 Million INR | 23.22% |
2016 FY | 808.03 Million INR | 7.66% |
2016 Q2 | 216.41 Million INR | -2.63% |
2015 Q3 | 202.69 Million INR | 8.84% |
2015 Q4 | 209.13 Million INR | 3.18% |
2015 FY | 750.56 Million INR | 18.5% |
2015 Q1 | 157.77 Million INR | 4.89% |
2015 Q2 | 186.24 Million INR | 18.04% |
2014 Q3 | 155.81 Million INR | -4.86% |
2014 FY | 633.37 Million INR | -11.16% |
2014 Q1 | 163.36 Million INR | -23.88% |
2014 Q2 | 163.76 Million INR | 0.25% |
2014 Q4 | 150.42 Million INR | -3.46% |
2013 Q1 | 155.58 Million INR | 0.38% |
2013 FY | 712.92 Million INR | -2.28% |
2013 Q4 | 214.62 Million INR | 30.2% |
2013 Q3 | 164.84 Million INR | -7.01% |
2013 Q2 | 177.27 Million INR | 13.94% |
2012 Q3 | 199.81 Million INR | 5.18% |
2012 Q2 | 189.96 Million INR | 2.81% |
2012 Q1 | 184.77 Million INR | -5.59% |
2012 FY | 729.55 Million INR | -6.33% |
2012 Q4 | 154.99 Million INR | -22.43% |
2011 Q2 | 204.53 Million INR | 0.0% |
2011 FY | 778.89 Million INR | 19.16% |
2011 Q4 | 195.7 Million INR | -3.7% |
2011 Q3 | 203.23 Million INR | -0.64% |
2010 FY | 653.64 Million INR | 30.48% |
2009 FY | 500.94 Million INR | 17.0% |
2008 FY | 428.16 Million INR | -9.37% |
2007 FY | 472.44 Million INR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Amrutanjan Health Care Limited | 2.09 Billion INR | 79.057% |
Biofil Chemicals and Pharmaceuticals Limited | 6.82 Million INR | -6330.352% |
Caplin Point Laboratories Limited | 2.17 Billion INR | 79.832% |
FDC Limited | 3.49 Billion INR | 87.469% |
Gufic Biosciences Limited | 1.18 Billion INR | 63.041% |
Hikal Limited | 4.46 Billion INR | 90.175% |
Ind-Swift Laboratories Limited | 2.12 Billion INR | 79.354% |
IOL Chemicals and Pharmaceuticals Limited | 2.2 Billion INR | 80.075% |
Kilitch Drugs (India) Limited | 412.42 Million INR | -6.334% |
Medico Remedies Limited | 59.67 Million INR | -634.897% |
Nectar Lifesciences Limited | 932.7 Million INR | 52.981% |
Par Drugs and Chemicals Limited | 58.28 Million INR | -652.384% |
RPG Life Sciences Limited | 1.63 Billion INR | 73.186% |
Sequent Scientific Limited | 2.9 Billion INR | 84.887% |
Shilpa Medicare Limited | 3.33 Billion INR | 86.847% |
Sigachi Industries Limited | 579.88 Million INR | 24.373% |
Themis Medicare Limited | 1.12 Billion INR | 61.045% |
Unichem Laboratories Limited | 6.72 Billion INR | 93.48% |
Venus Remedies Limited | 1.91 Billion INR | 77.115% |
Wanbury Limited | 978.96 Million INR | 55.203% |
ZIM Laboratories Limited | 1.01 Billion INR | 56.71% |
Lupin Limited | 125.09 Billion INR | 99.649% |
Innova Captab Limited | 931.03 Million INR | 52.896% |
Ind-Swift Limited | 946.56 Million INR | 53.669% |
Bajaj HealthCare Limited | 985.34 Million INR | 55.493% |
Aurobindo Pharma Limited | 55.65 Billion INR | 99.212% |
Solara Active Pharma Sciences Limited | 2.55 Billion INR | 82.83% |
AstraZeneca Pharma India Limited | 2.47 Billion INR | 82.27% |
Mangalam Drugs & Organics Limited | 162.22 Million INR | -170.329% |
Morepen Laboratories Limited | 1.98 Billion INR | 77.934% |
Laurus Labs Limited | 11.9 Billion INR | 96.318% |
Aarti Drugs Limited | 1.16 Billion INR | 62.436% |
Glenmark Life Sciences Limited | 11.64 Billion INR | 96.233% |
Alembic Limited | 872.45 Million INR | 49.734% |
Alembic Pharmaceuticals Limited | 15.86 Billion INR | 97.237% |
Glenmark Pharmaceuticals Limited | 46.95 Billion INR | 99.066% |
Vaishali Pharma Limited | 84.02 Million INR | -421.903% |
Aarti Pharmalabs Limited | 3.07 Billion INR | 85.735% |
Jubilant Pharmova Limited | 14.45 Billion INR | 96.966% |
Eris Lifesciences Limited | 4.94 Billion INR | 91.128% |
Windlas Biotech Limited | 1 Billion INR | 56.429% |
Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.716% |
Lincoln Pharmaceuticals Limited | 1.07 Billion INR | 59.174% |
Orchid Pharma Limited | 800.77 Million INR | 45.234% |
Albert David Limited | 1.02 Billion INR | 57.262% |
Hester Biosciences Limited | 908.84 Million INR | 51.746% |
Sakar Healthcare Limited | 204.07 Million INR | -114.892% |
Suven Pharmaceuticals Limited | 1.4 Billion INR | 68.737% |
Procter & Gamble Health Limited | 2.99 Billion INR | 85.359% |
Divi's Laboratories Limited | 14.17 Billion INR | 96.905% |
Mankind Pharma Limited | 29.27 Billion INR | 98.502% |
Neuland Laboratories Limited | 2.92 Billion INR | 85.031% |
J. B. Chemicals & Pharmaceuticals Limited | 14.79 Billion INR | 97.035% |
Zydus Lifesciences Limited | 125.21 Billion INR | 99.65% |
Wockhardt Limited | 8.48 Billion INR | 94.828% |
Bal Pharma Limited | 555.62 Million INR | 21.071% |
Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.543% |
Bliss GVS Pharma Limited | 1.41 Billion INR | 69.099% |
Alkem Laboratories Limited | 32.83 Billion INR | 98.664% |
Valiant Laboratories Limited | 138.02 Million INR | -217.723% |
Ajanta Pharma Limited | 30.46 Billion INR | 98.56% |
Bafna Pharmaceuticals Limited | 455.58 Million INR | 3.739% |
Aarey Drugs & Pharmaceuticals Limited | 14.21 Million INR | -2985.555% |
Granules India Limited | 10.31 Billion INR | 95.748% |
Medicamen Biotech Limited | 335.16 Million INR | -30.845% |
Ipca Laboratories Limited | 18.98 Billion INR | 97.69% |
Brooks Laboratories Limited | 51.18 Million INR | -756.878% |
Syncom Formulations (India) Limited | 345.63 Million INR | -26.883% |
Piramal Enterprises Limited | 63.65 Billion INR | 99.311% |
Torrent Pharmaceuticals Limited | 21.42 Billion INR | 97.953% |
NATCO Pharma Limited | 10.05 Billion INR | 95.64% |
Suven Life Sciences Limited | 109.75 Million INR | -299.59% |
Krebs Biochemicals & Industries Limited | 46.15 Million INR | -850.147% |
Strides Pharma Science Limited | 9.16 Billion INR | 95.214% |
Indoco Remedies Limited | 12.06 Billion INR | 96.364% |
Alpa Laboratories Limited | 127.38 Million INR | -244.285% |
Lasa Supergenerics Limited | 291.17 Million INR | -50.614% |
Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 85.747% |